Fatty liver disease (MASLD/MASH): who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PPAR 1
• AMPK 0
• GLP-1 7
• SGLT2 5
• NRF2 1
• SIRT1 0
• PNPLA3 6
• NLRP3 1
• mTOR 0
• AKT 0
• PI3K 0
• STAT3 0
• TLR4 0
• MAPK 0
• STING 0
• JNK 0
• TP53 0
• PINK1 0
• TNF 2
• HIF-1 0
• JAK 0
• GIP 1
• TFEB 0
• YAP 0
• CTNNB1 0
• ERK 0
• COX-2 0
• HSP90 0
• PTEN 0
• STK11 0
• APOE 0
• FTO 0
• HMGB1 0
• IL-6 0
• KEAP1 0
• PCSK9 0
• DPP-4 0
• GPX4 0
• VEGF 0
• FGFR 0
• IL-17 0
• PDGFR 0
• BDNF 0
• IL-1 0
• METTL3 0
• PKM2 0
• TREM2 0
• ACE2 0
• EGFR 0
• FAK 0
• IDH 0
• IDO1 0
• MDM2 0
• PARP 0
• PD-1 0
• RANKL 1
• ABL1 0
• ALK 0
• BCL-2 0
• CD38 0

24 of 1,999 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Subcellular Lipid Atlas: Decoding Organelle Identity with Targeted Lipid Profiling (LipID)

  Universitat Wien· Wien, Austria· EU contribution €1,500,000· until Jun 2032· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Metabolic Hepatoprotection to Enable Curative Cancer Therapy in Patients with Vulnerable Livers (SAFE-LIVER)

  Universitaet Bern· Bern, Switzerland· EU contribution €150,000· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Epigenomic Liquid Biopsy for Early Detection and Monitoring of Metabolic Dysfunction-Associated Steatohepatitis (cfChIP-MASH)

  The Hebrew University of Jerusalem· Jerusalem, Israel· EU contribution €150,000· until Jan 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Crossing borders of liver and adipose tissue (mis)communication: a novel translational approach to study molecular mechanisms and targets in metabolic dysfunction-associated steatotic liver disease (XB-LIVAT)

  Fondazione Italiana Fegato E.t.s.· Trieste, Italy· EU contribution €193,643· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploring the impact of Time-Restricted Eating and Exercise interventions on Gut microbiome of patients with hepatic steatosis and obesity – TREEGut

  Universidad de Granada· Granada, Spain· EU contribution €194,075· until Dec 2027· 2 countries

5 of 22 running projects, newest first. Listed amounts together: €71.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

  NCT03587831· University of Minnesota· Updated 30 Sept 2026

  “Study has been terminated due to poor recruitment and early evidence of futility”Registry text, quoted unchanged. Source

• Suspended

  NAFLD in Adolescents and Young Adults With PCOS

  NCT02506946· Columbia University· Updated 30 Sept 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Non-alcoholic Steatohepatitis Registry Platform Study

  NCT06123858· AstraZeneca· Updated 29 Jul 2026

  “Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion”Registry text, quoted unchanged. Source

• Withdrawn

  GLP-1 RA on Liver OMICS in MASLD

  NCT06982378· Medical College of Wisconsin· Updated 13 Jul 2026

  “no grant approved”Registry text, quoted unchanged. Source

• Withdrawn

  Assessment of Fatty Liver With Thermo-acoustic Device

  NCT04302051· Medical College of Wisconsin· Updated 10 Jul 2026

  “The sponsor withdrew from the study”Registry text, quoted unchanged. Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Galectin Therapeutics Inc.· Updated 30 Jun 2026

  “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.”Registry text, quoted unchanged. Source

• Terminated

  Prevention of NAFLD in Hispanic Children

  NCT05292352· Emory University· Updated 2 Jun 2026

  “Study was terminated due to a lack of funding. Data collection was completed for 12-month outcomes; however, funding limitations prevented follow-up for longer timeframes, and some outcomes were not fully collected.”Registry text, quoted unchanged. Source

• Terminated

  Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

  NCT06939816· Enyo Pharma· Updated 23 Apr 2026

  “Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.”Registry text, quoted unchanged. Source

• Terminated

  A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

  NCT06007651· Eli Lilly and Company· Updated 13 Apr 2026

  “Participants were not dosed in Part B as per the protocol.”Registry text, quoted unchanged. Source

• Withdrawn

  FCI Effectiveness in NAFLD Stratification

  NCT05827432· NHS Grampian· Updated 1 Apr 2026

  “Funding period ended.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• SMART Diets for MASLD

  NCT07459504· Michigan State University· Source

• Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· GlaxoSmithKline· Source

• ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

  NCT07850063· Boehringer Ingelheim· Source

• Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)

  NCT07933328· Regeneron Pharmaceuticals· Source

• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Boehringer Ingelheim· Source

• Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects With Type 2 Diabetes

  NCT06895018· Federico II University· Source

• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

  NCT05519475· Regeneron Pharmaceuticals· Source

• Isocaloric Navy-Bean Substitution in Adults With MASLD

  NCT07730853· Icahn School of Medicine at Mount Sinai· Source

• Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  NCT07631637· Regeneron Pharmaceuticals· Source

• A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07701993· GlaxoSmithKline· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 17
• Mendelian Randomization Analysis 45
• CRISPR-Cas Systems 3
• Gene Expression Profiling 105
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 3
• Exome Sequencing 2
• Proteomics 66
• Metabolomics 104
• Mass Spectrometry 10
• Flow Cytometry 3
• Immunohistochemistry 16
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 103
• Machine Learning 103
• Deep Learning 14
• Cohort Studies 173
• Genome-Wide Association Study 49

• An Enzyme-Triggered Self-Immobilizing Dual-Modal Probe for Precision Imaging and Sustained Gas Therapy of Early-Stage MASH.

  Anal Chem, Nov 2026

• Noninvasive Diagnosis of Hepatocellular Carcinoma Outside Guideline-Defined High-Risk Populations: Evolving Perspectives in the Era of MASLD.

  Korean J Radiol, Nov 2026

• Comparison of Data-Driven Phenotyping Systems for Metabolic Dysfunction-Associated Steatotic Liver Disease: Implications for Treatment Response.

  J Obes Metab Syndr, Oct 2026

• Patients with MASH experience worse health-related quality of life: a multinational real-world study using LiverMultiScan.

  Qual Life Res, Oct 2026

• Genome-wide analyses identify 60 loci associated with liver triglyceride content.

  Nat Genet, Oct 2026

• Diagnostic Value and Influencing Factors of Ultrasound-Derived Fat Fraction for Quantifying MASLD in Children.

  Liver Int, Oct 2026

• Small-Nerve Fibre Pathology in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Liver Fat/Inflammation and Improves with Weight Loss.

  Nutrients, Oct 2026

• Distinct Plasma Proteomic Signatures Distinguish MASLD From Non-Steatotic Individuals but Not From MetALD.

  Liver Int, Oct 2026

• Development of MASLD among survivors of breast or colorectal cancer (EVALUATE): protocol for a single-centre observational cross-sectional study.

  BMJ Open, Sept 2026

• Quantitative MRI to Assess Portal Pressure in Patients With Liver Disease: Validation at 3 T.

  NMR Biomed, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.